Clinical Trial Update: A Study of LY2510924 and Durvalumab in Participants With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial investigating LY2510924 in combination with durvalumab in participants with solid tumors; the study status is terminated with results posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• Durvalumab (durvalumab)
• LY2510924 (LY2510924)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Solid Tumor | Phase 1 | Status: TERMINATED | Results posted: 2019-08-12